Structural basis of pharmacological chaperoning for human β-galactosidase

GM1-gangliosidosis and Morquio B are rare lysosomal storage diseases associated with a neurodegenerative disorder or dwarfism and skeletal abnormalities, respectively. These diseases are caused by deficiencies in the lysosomal enzyme human β-Galactosidase (β-Gal), frequently related to misfolding and subsequent endoplasmic reticulum-associated degradation (ERAD) due to mutations in the β-Gal gene. Pharmacological chaperone (PC) therapy is a newly developed molecular therapeutic approach by using small molecule ligands of the mutant enzyme that are able to promote the correct folding, prevent ERAD and promote trafficking to the lysosome. Here, we present the enzymological properties of wild-type human β-Gal and two representative mutations in GM1 gangliosidosis Japanese patients (R201C and I51T). We have also evaluated the PC effect of two competitive inhibitors of β-Gal. Moreover, we determined the crystal structures of β-Gal in complex with these compouds and two structurally related analogues to elucidate the detailed atomic view of the recognition mechanism. All compounds bind to the active site of β-Gal with the sugar moiety making hydrogen bonds to active site residues. Moreover, the binding affinity, the enzyme selectivity and the PC potential are strongly affected by the mono or bicyclic structure of the core as well as the orientation, the nature and the length of the exocyclic substituent. These results provide understanding on the mechanism of action of β-Gal selective chaperoning by newly developed PC compounds.

Crystal structures of γ-glutamyltranspeptidase in complex with inhibitors

γ-Glutamyltranspeptidase (GGT; EC 2.3.2.2) is involved in the degradation of γ-glutamyl compounds such as glutathione (GSH; γ-glutamyl-cysteinyl-glycine) . A major physiological role of this enzyme is to cleave the extracellular GSH as a source of cysteine for intracellular glutathione biosynthesis. Another crucial role of GGT is to cleave glutathione-S-conjugates as a key step in detoxification of xenobiotics and drug metabolism. In mammals, GGT has been implicated in physiological disorders such as Parkinson's disease, other neurodegenerative diseases including Alzheimer's disease and cardiovascular disease. The indispensable roles played by GGT in GSH-mediated detoxification and cellular response to oxidative stress suggest that GGT is an attractive pharmaceutical target. We here report the binding mode of acivicin, a well-known glutamine antagonist, to B. subtilis GGT at 1.8 Å resolution showing that acivicin is bound to the Oγ atom of Thr403, the catalytic nucleophile of the enzyme, through its C3 atom [1]. The observed electron density around the C3 atom was best fitted to the planar and sp2 hybridized carbon, consistent with a simple nucleophilic substitution of Cl at the imino carbon by Oγ atom of Thr403. Furthermore, comparison of three bacterial enzymes, the GGTs from E. coli, H. pylori and B. subtilis in complex with acivicin, showed significant diversity in the orientation of the dihydroisoxazole ring among three GGTs. The differences are discussed in terms of the recognition of the α-amino and α-carboxy groups in preference to the dihydroisoxazole ring as observed in time-lapse soaking crystal structures of B. subtilis GGT with acivicin.

Crystal Chemistry and Physics of Perovskites with Small Cations at the A Site

Synthesis, crystal chemistry, and physics of perovskites with small cations at the A site are an emerging field in perovskite science. Properties of ABO3 perovskites with small cations at the A site (A = Sc and In; B = transition metals) will be reported. ScBO3 and InBO3 perovskites extend the corresponding families of perovskites with A = Y, La-Lu, and Bi and exhibit larger structural distortions. As a result of large distortions, they show, in many cases, distinct structural and magnetic properties. It is manifested in B-site-ordered monoclinic structures of ScMnO3 [Inorg. Chem. 52 (2013) 9692] and `InMnO3' [Angew. Chem.: Inter. Ed. 49 (2010) 7723]; an unusual superstructure of ScRhO3 and InRhO3 [Inorg. Chem. 52 (2013) 12005]; two magnetic transitions in ScCrO3 and InCrO3 with very close transition temperatures [Chem. Mater. 24 (2012) 2197]; and antiferromagnetic ground states and multiferroic properties of Sc2NiMnO6 and In2NiMnO6 [Inorg. Chem. 52 (2013) 14108]. Features of such perovskites, such as, transition metal doping into the A site, (Sc1-xBx)BO3, will be discussed. Special attention will be given to new spin-driven multiferroics Sc2NiMnO6 and In2NiMnO6.